Respiratory syncytial virus (RSV) infection is the most important cause of hospitalization in infants and is one of the leading global causes of infant mortality and as such its prevention through vaccination is a public health priority. While essential for the successful implementation of vaccine programs, there remains a paucity of data on the epidemiology of the virus in different settings and age groups and limited knowledge about virus transmission and the health-care costs of the disease. Such data are now needed to populate health economic models and to inform optimal approaches to disease control through vaccination.
Expert Rev Vaccines
149 - 152
RSV, cost–effectiveness mode, epidemiology, health economics, respiratory syncytial virus, vaccine, viral transmission, Costs and Cost Analysis, Disease Transmission, Infectious, Humans, Infant, Respiratory Syncytial Virus Infections, Respiratory Syncytial Virus Vaccines